Study guide

11.3 Antimicrobial Therapy, Host Modulation & Periodontal Maintenance

Saudi Dental Licensure Examination SDLE / SPLE - Dentist

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the SDLE: Format, Scoring, Eligibility, Attempts & Blueprint

2 Chapter 1: Operative Dentistry & Caries Management

1.1 Caries Etiology, Histopathology, and Risk Assessment (CAMBRA / ICDAS) 1.2 Cavity Preparation Principles and Tooth Isolation (Rubber Dam Mechanics) 1.3 Direct Composite Resin Restorations, Adhesion & Curing Dynamics 1.4 Indirect Inlays and Onlays, Minimally Invasive Restorations, Finishing and Repair

3 Chapter 2: Direct Restorations & Dental Biomaterials

2.1 Dental Amalgam Restorations, Matrix Systems & Proximal Contact Mechanics 2.2 Glass Ionomer Cements, Resin-Modified Glass Ionomers & Bioactive Materials 2.3 Dental Bonding Agents (Etch-and-Rinse vs. Self-Etch vs. Universal Systems) 2.4 Direct Pulp Capping, Indirect Pulp Capping & Pulpal Protection Liners

4 Chapter 3: Fixed Prosthodontics — Treatment Planning & Tooth Preparation

3.1 Fixed Partial Denture Treatment Planning: Abutments, Pontics and Endodontically Treated Teeth 3.2 Biological, Mechanical, and Esthetic Principles of Crown Preparations 3.3 Finish Lines and Margin Geometries (Chamfer, Shoulder, Feather-Edge) 3.4 Temporary/Provisional Restorations & Tissue Management (Gingival Retraction) 3.5 Impression Techniques, Digital Scanning & Working Casts

5 Chapter 4: Fixed Prosthodontics — Materials, Luting, Esthetics & Delivery

4.1 Dental Ceramics (Feldspathic, Lithium Disilicate, Zirconia) & Metal-Ceramics 4.2 Dental Cements and Luting Protocols (Zinc Phosphate, GI, RMGI, Resin) 4.3 Shade Selection, Color Science, and Esthetic Veneers 4.4 Fixed Prosthesis Try-In, Delivery, Complications and Repair

6 Chapter 5: Removable Partial Dentures

5.1 Removable Partial Dentures: Kennedy Classification, Rests, and Major Connectors 5.2 RPD Direct Retainers, Indirect Retainers & Surveying Principles 5.3 RPD Design Sequence, Mouth Preparation, Impressions, Try-In, Delivery and Maintenance

7 Chapter 6: Complete Dentures

6.1 Complete Denture Anatomy, Border Molding & Secondary Impressions 6.2 Maxillomandibular Relationships, Vertical Dimension & Occlusion Schemes 6.3 Complete Denture Diagnosis, Try-In, Insertion, Post-Insertion Problems and Relining

8 Chapter 7: Dental Anatomy, Occlusion & Articulators

7.1 Dental Anatomy: Tooth Notation, Permanent Tooth Morphology and Identification 7.2 Principles of Occlusion (Centric Relation, MIC, Canine Guidance, Group Function) 7.3 Articulators, Facebow Transfers & Occlusal Splints

9 Chapter 8: Basic Implantology

8.1 Basic Implantology: Patient Assessment, Treatment Planning and Implant Positioning 8.2 Implant Prosthodontics: Biomechanics, Abutment Types & Loading Protocols

10 Chapter 9: Ethics, Professionalism, Infection Control & Patient Safety

9.1 Ethics, Professionalism and Saudi Health Practice Law 9.2 Infection Control and Patient Safety in the Dental Clinic

11 Chapter 10: Periodontal Anatomy, Classification, Etiology & Pathology

10.1 Anatomy of the Periodontium and Biologic Width 10.2 2017 AAP/EFP World Workshop Classification (Staging and Grading) 10.3 Periodontal Microbiology, Host Response & Systemic Risk Factors 10.4 Applied Periodontal Pathology: Lesion Stages, Necrotizing Disease, Abscesses and Gingival Enlargement

12 Chapter 11: Periodontal Examination & Non-Surgical Therapy

11.1 Clinical Periodontal Assessment, Probing, Mobility & Furcation Involvement 11.2 Scaling and Root Planing, Ultrasonic Instrumentation & Full-Mouth Disinfection 11.3 Antimicrobial Therapy, Host Modulation & Periodontal Maintenance

13 Chapter 12: Surgical Periodontics, Peri-Implant Disease & Multidisciplinary Care

12.1 Periodontal Flap Surgery & Resective Osseous Surgery 12.2 Regenerative Periodontal Therapy (GTR, Bone Grafts, Enamel Matrix Derivatives) 12.3 Mucogingival Deformities, Soft Tissue Grafting & Peri-Implant Diseases (Mucositis vs. Peri-Implantitis) 12.4 Iatrogenic Factors, Occlusal Trauma and Multidisciplinary Periodontal Care

14 Chapter 13: Pulpal & Periapical Pathology, Diagnosis & Endodontic Treatment Planning

13.1 Pulpal Biology, Pathogenesis, and Diagnostic Terminology (AAE Classification) 13.2 Diagnostic Testing Modalities (Thermal, Electric, Percussion, Palpation, CBCT) 13.3 Endodontic Treatment Planning, Case Difficulty, Retreatment, Apical Surgery and Outcomes

15 Chapter 14: Endodontic Treatment: Anatomy, Access, Shaping & Irrigation

14.1 Internal Tooth Anatomy and Endodontic Access Cavity Preparation 14.2 Root Canal Instrumentation: Hand, Rotary, and Reciprocating Nickel-Titanium 14.3 Endodontic Irrigants (NaOCl, EDTA, CHX), Intracanal Medicaments & Smear Layer

16 Chapter 15: Obturation, Mishaps, Emergencies, Trauma & Endo-Perio Lesions

15.1 Root Canal Obturation Techniques (Cold Lateral, Warm Vertical, Bioceramic Sealers) 15.2 Management of Procedural Accidents (Ledges, Perforations, Separated Instruments) 15.3 Endodontic Emergencies, Flare-ups & Traumatic Dental Injuries (Luxations, Avulsion) 15.4 Endodontic-Periodontal Lesions, Cracked Teeth and Vertical Root Fractures

17 Chapter 16: Local Anesthesia, Surgical Principles, Biopsy & Exodontia

16.1 Local Anesthetics, Vasoconstrictors, Dosages & Nerve Block Techniques 16.2 Principles of Oral Surgery, Suturing, Wound Healing and Biopsy Techniques 16.3 Exodontia Principles, Surgical Extraction & Management of Impacted Third Molars 16.4 Post-Extraction Complications (Alveolar Osteitis, Hemorrhage, Oroantral Fistula)

18 Chapter 17: Odontogenic Infections, Maxillofacial Trauma & Dentofacial Deformities

17.1 Odontogenic Infections, Fascial Space Spread & Ludwig's Angina 17.2 Maxillofacial Trauma and Dentofacial Deformities

19 Chapter 18: Medical Emergencies & Medically Compromised Patients

18.1 Dental Office Medical Emergencies (Syncope, Anaphylaxis, Angina, Hypoglycemia) 18.2 Management of Medically Compromised Dental Patients (Cardiovascular, Anticoagulated, Diabetic) 18.3 Dental Management of Hematologic and Oncology Patients 18.4 Endocrine, Hepatic, Renal, Pulmonary, Neurological and Psychiatric Conditions in Dental Practice

20 Chapter 19: Oral Mucosal, Infectious, Immunologic & Salivary Gland Pathology

19.1 Benign and Malignant Oral Mucosal Lesions (Leukoplakia, Lichen Planus, OSCC) 19.2 Microbiological Infections of the Oral Mucosa: Fungal, Viral and Bacterial 19.3 Immunologic and Allergic Conditions, Reactive Lesions and Physical or Chemical Injuries 19.4 Salivary Gland Diseases: Obstruction, Infection, Sjögren Syndrome and Tumors

21 Chapter 20: Jaw Pathology & Abnormalities of Teeth

20.1 Odontogenic Cysts and Tumors (Radicular Cyst, Dentigerous Cyst, OKCs, Ameloblastoma) 20.2 Bone Pathology of the Jaws: Fibro-Osseous Lesions, Giant Cell Lesions, Osteomyelitis and Malignancy 20.3 Abnormalities of Teeth and Developmental Defects of the Oral Region

22 Chapter 21: Orofacial Pain, TMD & Neuromuscular Disorders

21.1 Differential Diagnosis of Odontogenic vs. Non-Odontogenic Orofacial Pain 21.2 Temporomandibular Disorders and Neuromuscular Conditions

23 Chapter 22: Orthodontic Growth, Diagnosis & Treatment Planning

22.1 Craniofacial Growth, Development & Angle's Malocclusion Classification 22.2 Cephalometric Landmarks, Analysis & Biology of Orthodontic Tooth Movement 22.3 Etiology of Malocclusion, Orthodontic Diagnosis and Treatment Planning

24 Chapter 23: Orthodontic Treatment: Interceptive, Skeletal, Canines & Fixed Appliances

23.1 Interceptive Orthodontics, Serial Extraction & Space Maintainers (Band and Loop, Nance, Lingual Arch) 23.2 Management of Class I, Class II, Class III and Skeletal Problems 23.3 Ectopic and Impacted Maxillary Canines 23.4 Fixed Appliances, Anchorage, Adult Orthodontics and Retention

25 Chapter 24: Pediatric Dentistry: Development, Behavior, Caries & Restorative Care

24.1 Dental Development, Eruption Chronology and Examination of the Child 24.2 Pediatric Behavior Guidance, Nitrous Oxide & Early Childhood Caries (ECC) 24.3 Pediatric Caries Prevention and Restorative Dentistry: Sealants, ART, Crowns and Material Choice

26 Chapter 25: Pediatric Pulp Therapy, Pain Management, Oral Surgery, Trauma & Child Protection

25.1 Pediatric Pulp Therapy (Pulpotomy vs. Pulpectomy) and Stainless Steel Crowns 25.2 Pediatric Local Anesthesia, Pain Management and Pediatric Oral Surgery 25.3 Traumatic Injuries to the Primary Dentition and Recognition of Child Abuse and Neglect

11.3 Antimicrobial Therapy, Host Modulation & Periodontal Maintenance

Key Takeaways Explain This Topic AI

Systemic antimicrobials are strictly adjunctive to mechanical instrumentation and indicated exclusively in Stage III/IV Grade C periodontitis, refractory periodontitis, or acute necrotizing conditions—never as monotherapy or for routine chronic periodontitis.

The gold-standard synergistic antibiotic combination is Amoxicillin 500 mg TID plus Metronidazole 250–500 mg TID for 7 to 8 days, delivering dual bactericidal action against facultative Aggregatibacter actinomycetemcomitans and strict anaerobic Porphyromonas gingivalis.

Local drug delivery systems (PerioChip, Arestin, Atridox) deliver sustained subgingival release of antimicrobials at 100- to 1,000-fold higher local concentrations without systemic side effects, indicated for isolated recurrent bleeding pockets ≥5 mm at re-evaluation.

Sub-antimicrobial dose doxycycline (SDD / Periostat, 20 mg BID for 3 to 9 months) operates via host modulation by inhibiting collagenolytic matrix metalloproteinases (MMP-8 and MMP-13) without selecting for antibiotic-resistant bacteria.

Re-evaluation is mandatory at 4 to 8 weeks post-SRP to assess long junctional epithelial healing, while supportive periodontal therapy (SPT) requires strict 3-month recall intervals dictated by the 9- to 12-week repopulation cycle of subgingival periopathogens.

Last updated: October 2026

While mechanical debridement remains the primary intervention in periodontics, mechanical access alone cannot predictably eradicate tissue-invasive pathogens residing within deep pocket soft tissue walls, furcations, dentinal tubules, or mucosal reservoirs. When indicated, pharmacological agents serve as crucial adjuncts to suppress pathogenic microflora and modulate excessive host tissue breakdown.

  • Systemic Antimicrobial Therapy in Periodontics
  • The Biofilm Barrier and Antimicrobial Stewardship

Bacteria within a structured subgingival biofilm are up to 1,000 times more resistant to antimicrobial agents than planktonic cells. Extracellular polymeric substances (EPS) physically impede drug diffusion, while bacterial dormancy in deep layers limits the efficacy of cell-wall-active agents. Therefore, systemic antibiotics must NEVER be prescribed as monotherapy without prior mechanical debridement to disrupt the protective biofilm structure.

Strict Clinical Indications

Systemic antibiotics are not indicated for routine plaque-induced gingivitis or mild-to-moderate chronic periodontitis. Their use is strictly reserved for:

Stage III or Stage IV Periodontitis with Grade C progression (rapidly progressive / formerly aggressive periodontitis).

Generalized severe periodontitis in young adults (<35 years of age).

Refractory Periodontitis: Patients exhibiting continued attachment loss despite repeated, diligent mechanical debridement and exemplary oral hygiene.

Acute Multiple Periodontal Abscesses presenting with systemic manifestations (fever, lymphadenopathy, trismus, malaise).

Necrotizing Ulcerative Periodontitis (NUP) in immunocompromised individuals.

The Gold-Standard Combination: Amoxicillin + Metronidazole

Dosage & Duration: Amoxicillin 500 mg TID + Metronidazole 250 mg or 500 mg TID for 7 to 8 days (the Van Winkelhoff cocktail).

Synergistic Mechanism of Action:

Amoxicillin: A bactericidal aminopenicillin that binds penicillin-binding proteins (PBPs), inhibiting bacterial cell wall peptidoglycan synthesis. Active against facultative gram-negative and gram-positive rods, notably Aggregatibacter actinomycetemcomitans ( A.a. ).

Metronidazole: A bactericidal nitroimidazole that is actively reduced inside anaerobic cells to toxic short-lived nitro radicals, disrupting bacterial DNA. Highly potent against obligate gram-negative anaerobes ( Porphyromonas gingivalis , Tannerella forsythia , Treponema denticola ).

Synergy: A.a. can invade gingival epithelial cells and is relatively tolerant to metronidazole alone, whereas several subgingival anaerobes (notably Prevotella species) produce beta-lactamases that degrade penicillins. Administered together, metronidazole eliminates the strict anaerobes, including beta-lactamase producers, while amoxicillin eradicates tissue-invasive A.a. , achieving synergistic bacterial clearance.

Critical Pharmacological Precautions and Interactions

Warning

Metronidazole irreversibly inhibits hepatic aldehyde dehydrogenase. Ingestion of any ethanol (including alcohol-containing mouthwashes, elixirs, or culinary sauces) during metronidazole therapy and for at least 3 days (72 hours) after the last dose produces a severe disulfiram-like (Antabuse) reaction characterized by acute acetaldehyde toxicity, violent projectile vomiting, severe abdominal cramping, tachycardia, throbbing headache, and hemodynamic hypotension.

Disulfiram-like (Antabuse) Reaction: Metronidazole inhibits hepatic aldehyde dehydrogenase. Ingestion of any alcohol during therapy and for at least 3 days after the last dose (FDA labelling) results in acute acetaldehyde toxicity, triggering severe nausea, projectile vomiting, violent abdominal cramping, tachycardia, throbbing headache, and hypotension.

Warfarin Interaction: Metronidazole inhibits cytochrome P450 CYP2C9 and depletes vitamin K-producing intestinal flora, markedly potentiating the anticoagulant effect of warfarin and substantially elevating the International Normalized Ratio (INR), leading to severe hemorrhage risk.

Common Adverse Effects: Metallic taste (dysgeusia), gastrointestinal disturbance, and nausea.

Alternative Regimens for Penicillin-Allergic Patients

Azithromycin: 500 mg orally once daily on Day 1, followed by 250 mg once daily on Days 2 through 5. Concentrates intracellularly within phagocytes, macrophages, and fibroblasts, delivering sustained therapeutic levels in gingival crevicular fluid (GCF) for several days post-completion.

Clindamycin: 300 mg QID for 7 to 10 days. Exceptional bone penetration; carries a notable risk of Clostridioides difficile -associated pseudomembranous colitis.

Ciprofloxacin + Metronidazole: Ciprofloxacin 500 mg BID + Metronidazole 500 mg BID for 8 days. A non-penicillin regimen specifically targeting facultative gram-negative rods ( A.a. ) and strict anaerobes.

Local Drug Delivery (LDD) Systems

Local drug delivery involves placing a controlled-release or sustained-release vehicle directly into a diseased periodontal pocket, achieving subgingival drug concentrations 100 to 1,000 times higher than systemic administration without producing systemic adverse effects or altering gastrointestinal microflora. LOCAL DRUG DELIVERY (LDD) SYSTEMS

  • PERIOCHIP (2.5 mg) ARESTIN (1 mg) ATRIDOX (42.5 mg)
  • [Chlorhexidine Chip] [Minocycline Microspheres] [Doxycycline Gel 10%]
  • +-------------+ o o o o o o o o ~~~~~~~~~~~~~~~~~
  • | Gelatin | o PGLA Polymer o | Syringe-Mixed |
  • | Matrix | o Microspheres o | In-Situ Solid |
  • +-------------+ o o o o o o o ~~~~~~~~~~~~~~~~~~
  • Hydrolyzed gelatin • Bioresorbable polymer • Poly(DL-lactide) gel
  • Releases CHX: 7-10 days • Releases Mino: 14 days • Releases Doxy: 7-14 days
  • Zero bacterial resistance • Tetracycline derivative • Solidifies on GCF contact
  • Indications for Local Drug Delivery

Indicated for isolated, persistent, or recurrent pockets ≥ 5 mm \ge 5\text{ mm} ≥ 5 mm with bleeding on probing (BOP) at the 4-to-8-week re-evaluation following initial scaling and root planing.

Contraindications: Generalized severe periodontitis (where systemic or surgical intervention is needed), intrabony defects requiring surgical regeneration, or pockets < 5 mm <5\text{ mm} < 5 mm .

Controlled-Release Formulations

Chlorhexidine Gluconate Chip (PerioChip):

Composition: 2.5 mg chlorhexidine gluconate incorporated into a cross-linked hydrolyzed gelatin matrix.

Kinetics: Biodegradable; releases chlorhexidine subgingivally over 7 to 10 days , maintaining GCF levels > 125 μ g/mL >125\ \mu\text{g/mL} > 125 μ g/mL .

Advantages: Resorbs completely (does not require physical removal); chlorhexidine carries zero risk of developing bacterial resistance .

Minocycline Hydrochloride Microspheres (Arestin):

Composition: 1 mg minocycline encapsulated within bioresorbable poly(glycolide-co-dl-lactide) (PGLA) microspheres.

Kinetics: Dry powder delivered into the pocket via a specialized cartridge; adheres to moist pocket walls and hydrolyzes over 14 days .

Precautions: Broad-spectrum tetracycline derivative; contraindicated in tetracycline hypersensitivity, pregnant women, and pediatric patients < 8 <8 < 8 years of age due to intrinsic enamel discoloration.

Doxycycline Hyclate 10% Gel (Atridox):

Composition: 42.5 mg doxycycline hyclate contained in a two-syringe mixing system using the Atrigel delivery polymer (poly[DL-lactide] dissolved in N-methyl-2-pyrrolidone).

Kinetics: Injected as a liquid that solidifies into a wax-like matrix upon contact with GCF; controlled release over 7 to 14 days .

Host Modulation Therapy (HMT)

Host modulation therapy aims to restore balance between pro-inflammatory destructive mediators and protective host mechanisms, dampening excessive enzyme-mediated breakdown of periodontal connective tissue and alveolar bone. HOST MODULATION: SDD MECHANISM OF ACTION

  • Periodontal Biofilm Pathogens (P. gingivalis, A.a., Treponema)
  • │
  • ▼
  • Host Immune-Inflammatory Response
  • (PMNs, Monocytes, Macrophages)
  • │
  • ┌────────────────┴────────────────┐
  • ▼ ▼
  • Pro-inflammatory Cytokines Collagenolytic Enzymes
  • (IL-1β, TNF-α, PGE₂) (MMP-8, MMP-13)
  • │ │
  • │ [PERIOSTAT] │ [PERIOSTAT]
  • │ (Doxycycline 20 mg BID) │ (Direct Inhibition
  • │ X Suppresses │ of Catalytic Site)
  • ▼ │ ▼
  • Osteoclast Activation ◄──────────── Alveolar Bone & PDL
  • (Alveolar Resorption) Collagen Destruction
  • Sub-Antimicrobial Dose Doxycycline (SDD / Periostat)

Dosing Protocol: 20 mg orally twice daily (BID) taken 1 hour before meals for a duration of 3 to 9 months , administered as an adjunct to mechanical scaling and root planing.

Biochemical Mechanism:

At standard antibiotic doses (100–200 mg/day), doxycycline yields serum levels of 2.0 to 5.0 μ g/mL \mu\text{g/mL} μ g/mL , which exceeds the minimum inhibitory concentration (MIC) needed to kill or inhibit bacteria.

At a sub-antimicrobial dose of 20 mg BID, peak plasma levels reach only 0.6 to 0.8 μ g/mL \mu\text{g/mL} μ g/mL , which is strictly below the antimicrobial threshold .

Enzymatic Inhibition: Doxycycline binds divalent zinc ( Z n 2 + Zn^{2+} Z n 2 + ) and calcium ( C a 2 + Ca^{2+} C a 2 + ) ions within the active catalytic site of host Matrix Metalloproteinases , specifically MMP-8 (neutrophil collagenase) and MMP-13 (collagenase-3) . This directly halts the enzymatic cleavage of Type I alveolar collagen.

Downregulation of Cytokines: Suppresses the production of interleukin-1 β \beta β (IL-1 β \beta β ), tumor necrosis factor- α \alpha α (TNF- α \alpha α ), and prostaglandin E 2 E_2 E 2 ​ ( PGE 2 \text{PGE}_2 PGE 2 ​ ), while downregulating osteoclastic bone resorption via RANKL suppression.

Safety Profile: Multi-year clinical trials demonstrate that SDD does NOT induce antimicrobial resistance, alter normal subgingival, gastrointestinal, or vaginal microflora, or lead to opportunistic fungal overgrowth.

Periodontal Re-Evaluation Protocol PHASE I RE-EVALUATION DECISION ALGORITHM

  • Phase I Non-Surgical Debridement (SRP)
  • │
  • ▼ Wait 4 to 8 Weeks
  • [Comprehensive Re-Evaluation Visit]
  • │
  • ┌──────────────────────┼──────────────────────┐
  • ▼ ▼ ▼
  • PD ≤ 4 mm, PD 4-5 mm, PD ≥ 6 mm,
  • No BOP Localized BOP Deep Infrabony / Furcation
  • │ │ │
  • ▼ ▼ ▼
  • [Periodontal [Localized SRP / [Phase II Surgical
  • Maintenance] Local Drug Delivery] Periodontal Therapy]
  • Timing: The 4-to-8-Week Window

Re-evaluation must be scheduled between 4 and 8 weeks post-instrumentation:

Evaluating < 4 <4 < 4 Weeks is Premature: Following mechanical instrumentation, initial epithelial closure occurs within 1 to 2 weeks, but connective tissue collagen maturation and reorganization require at least 4 weeks. Probing before 4 weeks will tear the fragile, immature hemidesmosomes of the healing long junctional epithelium.

Evaluating > 8 >8 > 8 to 12 Weeks is Delayed: Postponing re-evaluation beyond 8 to 12 weeks allows subgingival periopathogens to recolonize unhealed pockets, obscuring the clinical efficacy of initial debridement.

Re-Evaluation Assessment and Triage

Resolved Sites (PD ≤ 4 mm \le 4\text{ mm} ≤ 4 mm , no BOP): Transition directly to Supportive Periodontal Therapy (SPT) .

Persistent Shallow/Moderate Pockets (4 to 5 mm) with Localized BOP: Perform localized re-instrumentation, reinforce personal plaque control, or place local drug delivery vehicles.

Persistent Deep Pockets ( ≥ 6 mm \ge 6\text{ mm} ≥ 6 mm ) with BOP, Infrabony Defects, or Furcations: Indication for Phase II surgical periodontal therapy (access flap surgery, osseous resective surgery, or regenerative procedures).

Supportive Periodontal Therapy (Periodontal Maintenance)

Periodontitis is a chronic, non-curable, recurrent inflammatory disease. Once treated, patients must remain in lifelong Supportive Periodontal Therapy (SPT) to prevent recurrence and secondary tooth loss.

The Biological Rationale for the 3-Month Recall Interval

Subgingival Biofilm Repopulation Kinetics: Landmark investigations by Socransky, Slots, and Magnusson demonstrated that thorough mechanical scaling and root planing clears subgingival pathogens, temporarily establishing a benign flora of facultative gram-positive cocci and rods.

Repopulation Timeline: Virulent, tissue-destructive gram-negative anaerobes ( P. gingivalis , T. forsythia , T. denticola , and spirochetes) begin reappearing in subgingival pockets by 6 to 9 weeks .

The Climax Community: By 9 to 12 weeks (approximately 3 months), the pathogenic subgingival climax community has returned to pre-treatment levels if not professionally disrupted. Therefore, a 3-month recall interval is biologically essential to mechanically disrupt the subgingival biofilm before active connective tissue attachment loss can re-initiate.

Components of a Periodontal Maintenance Visit

Medical and Dental History Update: Review systemic risk factors (diabetes control, smoking cessation, medications).

Periodontal Re-examination: Complete 6-site probing depths, CAL, BOP, mobility, and furcation check.

Oral Hygiene Reinforcement: Review patient plaque index; personalize interdental cleaning instruction.

Selective Debridement: Ultrasonic and hand debridement targeted specifically to bleeding or deepened sites.

Polishing & Fluoride: Application of topical fluoride to prevent root surface caries on exposed root cementum.

Pharmacological Agents in Periodontal Therapy

Classification Representative Agent Standard Dosage & Administration Primary Mechanism of Action Specific Periodontal Indication

Systemic Antibiotic Combination Amoxicillin + Metronidazole Amox 500 mg TID + Metro 250–500 mg TID for 7–8 days Dual bactericidal synergy: cell-wall lysis (Amox) + DNA disruption (Metro) Stage III/IV Grade C periodontitis; refractory periodontitis

Systemic Macrolide Azithromycin 500 mg Day 1; 250 mg Days 2–5 once daily Inhibits 50S ribosomal protein synthesis; concentrates in phagocytes Penicillin-allergic patients with severe periodontitis

Local Drug Delivery (Chip) Chlorhexidine Gluconate (PerioChip) 2.5 mg hydrolyzed gelatin chip inserted into pocket Sustained antiseptic membrane lysis over 7–10 days; zero resistance Isolated persistent/recurrent pockets ≥ 5 mm \ge 5\text{ mm} ≥ 5 mm with BOP

Local Drug Delivery (Microspheres) Minocycline HCl (Arestin) 1 mg bioresorbable PGLA microspheres cartridge Sustained bacteriostatic 30S ribosomal inhibition over 14 days Localized deep pockets ≥ 5 mm \ge 5\text{ mm} ≥ 5 mm with BOP at re-evaluation

Local Drug Delivery (Gel) Doxycycline Hyclate 10% (Atridox) 42.5 mg in-situ solidifying syringe polymer Controlled bacteriostatic release over 7–14 days Localized recurrent pockets ≥ 5 mm \ge 5\text{ mm} ≥ 5 mm post-SRP

Host Modulation Therapy (HMT) Sub-antimicrobial Doxycycline (Periostat) 20 mg orally twice daily (BID) for 3 to 9 months Non-antibiotic direct inhibition of host collagenases (MMP-8 & MMP-13) Adjunct to SRP in generalized Stage III/IV periodontitis

Topical Antiseptic Rinse Chlorhexidine Gluconate 0.12% – 0.2% 15 mL rinse for 30–60 sec BID for 2 weeks Binds anionic cell walls causing bacterial membrane rupture Full-mouth disinfection; post-surgical plaque control

Loading diagram... Periodontal Pharmacological and Maintenance Decision Framework